GlycoMimetics, Inc. (GLYC)
Market Cap | 17.33M |
Revenue (ttm) | 10,000 |
Net Income (ttm) | -37.28M |
Shares Out | 64.46M |
EPS (ttm) | -0.58 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,076,921 |
Open | 0.296 |
Previous Close | 0.296 |
Day's Range | 0.268 - 0.296 |
52-Week Range | 0.240 - 3.530 |
Beta | 2.14 |
Analysts | Buy |
Price Target | 12.00 (+4,364.29%) |
Earnings Date | Jul 31, 2024 |
About GLYC
GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protei... [Read more]
Financial Performance
In 2023, GlycoMimetics's revenue was $10,000, a decrease of -86.67% compared to the previous year's $75,000. Losses were -$36.90 million, -20.97% less than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for GLYC stock is "Buy." The 12-month stock price forecast is $12.0, which is an increase of 4,364.29% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/z/m/press17-2460948.jpg)
GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di...
![](https://cdn.snapi.dev/images/v1/0/z/press16-2452490.jpg)
GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory dis...
![](https://cdn.snapi.dev/images/v1/7/2/press4-2411367.jpg)
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di...
![](https://cdn.snapi.dev/images/v1/c/z/conf11-2390633.jpg)
GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, ...
![](https://cdn.snapi.dev/images/v1/q/b/press19-2343510.jpg)
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di...
![](https://cdn.snapi.dev/images/v1/3/y/conf18-2321799.jpg)
GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report fourth quarter and 2023 full year financial results on We...
![](https://cdn.snapi.dev/images/v1/z/l/press18-2293121.jpg)
GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Harout Semerjian, Chief Executive Officer, will participate in the Leukemia Panel at the Cowen 44th Annual Heal...
![](https://cdn.snapi.dev/images/v1/q/z/press1-2271133.jpg)
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (the “Company”) (NASDAQ:GLYC) today announced that the Compensation Committee of the Company's Board of Directors approved the grant on February 6,...
![](https://cdn.snapi.dev/images/v1/b/p/press9-2216085.jpg)
GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di...
![](https://cdn.snapi.dev/images/v1/a/k/press5-2190422.jpg)
GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di...
![](https://cdn.snapi.dev/images/v1/a/v/press7-2149281.jpg)
GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthca...
![](https://cdn.snapi.dev/images/v1/b/y/press11-2138629.jpg)
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di...
![](https://cdn.snapi.dev/images/v1/n/1/conf11-2112891.jpg)
GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report third quarter 2023 financial results on Friday, November ...
![](https://cdn.snapi.dev/images/v1/e/k/press19-2050916.jpg)
GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di...
![](https://cdn.snapi.dev/images/v1/w/q/conf5-2048926.jpg)
GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Co...
![](https://cdn.snapi.dev/images/v1/w/4/press15-2026690.jpg)
GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (the “Company”) (NASDAQ:GLYC) today announced that the Compensation Committee of the Company's Board of Directors approved the grant on August 14 ,...
![](https://cdn.snapi.dev/images/v1/c/i/press4-2001015.jpg)
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di...
![](https://cdn.snapi.dev/images/v1/a/1/conf19-1977529.jpg)
GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report second quarter 2023 financial results on Wednesday, Augus...
![](https://cdn.snapi.dev/images/v1/j/e/press17-1947554.jpg)
GlycoMimetics Announces Its Addition to the Russell Microcap® Index
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory di...
![](https://cdn.snapi.dev/images/v1/5/t/press2-1935483.jpg)
GlycoMimetics Announces U.S. Food and Drug Administration Clears Addition of Time-based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory dis...
![](https://cdn.snapi.dev/images/v1/q/2/press14-1913819.jpg)
GlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare Conference
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conf...
![](https://cdn.snapi.dev/images/v1/x/j/press7-1867881.jpg)
GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory dis...
![](https://cdn.snapi.dev/images/v1/n/y/conf9-1854365.jpg)
GlycoMimetics to Report First Quarter 2023 Financial Results on May 3, 2023
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report first quarter 2023 financial results on Wednesday, May 3,...
![](https://cdn.snapi.dev/images/v1/0/0/press14-1816663.jpg)
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory dis...
![](https://cdn.snapi.dev/images/v1/b/x/conf2-1799645.jpg)
GlycoMimetics to Report Fourth Quarter and 2022 Full Year Financial Results on March 29, 2023
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report fourth quarter and 2022 full year financial results on We...